. The ability of heparin, hirudin, and synthetic thrombin in¬ hibitors to block FPA release by soluble and fibrinassociated thrombin was evaluated in citrated plasma (Fig 4-6 ). All thrombin inhibitors produced concen¬ tration-dependent inhibition of FPA release mediated by fluid-phase thrombin. Heparin, however, was much less effective against fibrin-bound thrombin, requiring a 20-fold higher concentration to block 70% of the clot-bound enzyme compared with equivalent inhibi¬ tion of soluble thrombin (Fig 4) . Hirudin was 50% as effective against clot-bound compared with fluidphase thrombin, while smaller hirudin analogs and Dphenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK), a synthetic inhibitor, were equipotentagainst the two forms of the serine protease (Fig 5, 6 ). It was 1, 578 hypothesized that the smaller direct thrombin inhibi¬ tors are better able to penetrate into the interstices of the fibrin meshwork and thus achieve more potent in¬ hibition of fibrin-bound thrombin (Table 1) .
Hirudin binds to thrombin at the catalytic site and also at the anion binding exosite by an anionic hirudin tail fragment (Fig 2) . The The antithrombin activity of hirugen is due to its interaction with the anion-binding exosite (Fig 2) (Fig 2, 7) . These 
